| Item | Question                                                                 | Authors’ Response (place “-” if not applicable) |
|------|------------------------------------------------------------------------|-------------------------------------------------|
| 1    | Would you like to share data collected for your study to others?       | Yes                                             |
| 2    | If not, would you like to share the reason for your decision?         | -                                               |
| 3    | What data in particular will be shared?                                | The survival data in particular will be shared. |
| 4    | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested. |
| 5    | When will data availability begin?                                     | From the publication date.                      |
| 6    | When will data availability end?                                       | Two years within the publication date, since the technique or survival date may be updated over time. |
| 7    | To whom will you share the data?                                      | Medical oncologists and Infectious Disease specialist who are interested in studies. |
| 8    | For what type of analysis or purpose?                                  | To evaluate the safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection. |
| 9    | How or where can the data/documents be obtained?                      | Emails could be sent to the address below to obtain the shared data: 21218034@zju.edu.cn |
| 10   | Any other restrictions?                                                | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |